| J9271 | Injection, pembrolizumab, 1 mg | 14,200 | $40 | $610.6K |
| J0897 | Injection, denosumab, 1 mg | 11,160 | $20 | $200.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 1,830 | $100 | $183.1K |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | 2,570 | $30 | $64.3K |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 10,160 | $10 | $61K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | 430 | $110 | $47.5K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 350 | $110 | $39K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 340 | $100 | $33.4K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 970 | $30 | $24.2K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 160 | $140 | $22.7K |